Biocon

In News

Biocon chair Kiran Mazumdar-Shaw charts five-year succession plan, names niece as successor - Reuters

Reuters - May 05, 2026

Biocon's next chapter: A leadership team built for the next decade - Business Standard

Business Standard - May 27, 2026

Biocon Launches Two Denosumab Biosimilars, Aukelso and Bosaya, in US - Contract Pharma

Contract Pharma - Apr 07, 2026

Biocon Q4FY26 Total Income at Rs 4,569 Cr EBITDA at Rs 1,073 Cr; Net Profit - Biocon

Biocon - May 07, 2026

Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia - Business Wire

Business Wire - Apr 21, 2026

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

PR Newswire - Dec 06, 2025

Health Canada approves Biocon’s two denosumab biosimilars - Pharmaceutical Technology

Pharmaceutical Technology - Apr 22, 2026

Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Fierce Pharma - Dec 09, 2025

How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions - Yahoo Finance

Yahoo Finance - May 04, 2026

Biocon’s Bold Integration: Unifying Biosimilars and Generics to Redefine Global Affordable Access - Endpoints News

Endpoints News - May 04, 2026

Biocon to Add Pembrolizumab, Nivolumab & Trastuzumab SC Biosimilars to its Portfolio - Pearce IP

Pearce IP - Jan 06, 2026

Biocon Limited to integrate Biocon Biologics - The Pharma Letter

The Pharma Letter - Dec 09, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment